PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Cristian Rodriguez-Aguayo,Emine Bayraktar,Cristina Ivan,Burcu Aslan,Junhua Mai,Guangan He,Lingegowda S Mangala,Dahai Jiang,Archana S Nagaraja,Bulent Ozpolat,Arturo Chavez-Reyes,Mauro Ferrari,Rahul Mitra,Zahid H Siddik,Haifa Shen,Xianbin Yang,Anil K Sood,Gabriel Lopez-Berestein

EBioMedicine（2019）

引用 35|浏览115

暂无评分

摘要

These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. FUND: National Institutes of Health/National Cancer Institute, USA.

查看译文

关键词

PTGER3,Ovarian cancer,RNA interference,Chemically modified siRNA,Cisplatin resistance,ETS1,ELK1,CFTR

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要